Drug Access Listing

Oral

Not specified

Group 2*  

Eligibility:

• Abiraterone (plus prednisone) in combination with ADT for treatment of patients with mCSPC defined as:
  • No prior ADT in the metastatic setting, OR
  • Within 6 months of beginning ADT for metastatic disease, OR
  • > 1 year since prior ADT for early-stage disease with good performance status
• Patients may receive only one of these agents (apalutamide, enzalutamide, or abiraterone) in this setting and switching only if intolerant (without progression)

*Cancer Drugs in group 2 of the Schedule may be dispensed by a Cancer Pharmacy only if the initial prescription is written by a Cancer Centre Medical Staff member, but a subsequent prescription for the same patient may be written by a person authorized by Alberta Health Services to prescribe Cancer Drugs and who is a physician, a regulated member under the Health Professions Act authorized to prescribe drugs, or a person authorized to prescribe drugs pursuant to another enactment.

AHS Outpatient Cancer Drug Benefit Program [3-22]

Janssen (Janssen BioAdvance Patient Assistance Program): Click Here   
 

Oral

Not specified

Group 2* 

Eligibility:
Abiraterone for the treatment of mCRPC
•    May be used following progression on or intolerance to apalutamide/enzalutamide/ darolutamide used in nmCRPC setting
•    May be used following apalutamide/enzalutamide used in mCSPC setting for patients who discontinued due to intolerance or toxicity. Not to be used in patients whose mCSPC has previously progressed on apalutamide/enzalutamide, unless they are unable tolerate, or are not candidates for other therapeutic options. Patients must not have progressed previously on abiraterone.
•    May be used after progression on docetaxel if not received before
•    
*Cancer Drugs in group 2 of the Schedule may be dispensed by a Cancer Pharmacy only if the initial prescription is written by a Cancer Centre Medical Staff member, but a subsequent prescription for the same patient may be written by a person authorized by Alberta Health Services to prescribe Cancer Drugs and who is a physician, a regulated member under the Health Professions Act authorized to prescribe drugs, or a person authorized to prescribe drugs pursuant to another enactment.
 

AHS Outpatient Cancer Drug Benefit Program [3-22]

Janssen (Janssen BioAdvance Patient Assistance Program): Access Here
 

70 mg PO

Multiple

Regular Benefit: No form required

Alberta Health Drug Benefit List [3-22]

Apotex: Access Here

Oral

Not Specified

Group 2* 

Eligibility:
Abiraterone for the treatment of mCRPC

• May be used following progression on or intolerance to apalutamide/enzalutamide/ darolutamide used in nmCRPC setting
• May be used following apalutamide/enzalutamide used in mCSPC setting for patients who discontinued due to intolerance or toxicity. Not to be used in patients whose mCSPC has previously progressed on apalutamide/enzalutamide, unless they are unable tolerate, or are not candidates for other therapeutic options. Patients must not have progressed previously on abiraterone.
• May be used after progression on docetaxel if not received before

*Cancer Drugs in group 2 of the Schedule may be dispensed by a Cancer Pharmacy only if the initial prescription is written by a Cancer Centre Medical Staff member, but a subsequent prescription for the same patient may be written by a person authorized by Alberta Health Services to prescribe Cancer Drugs and who is a physician, a regulated member under the Health Professions Act authorized to prescribe drugs, or a person authorized to prescribe drugs pursuant to another enactment.

AHS Outpatient Cancer Drug Benefit Program

JAMP (JAMP Care): Click Here

Sentrex Health Solutions: Click Here

Pharma-science: Click Here

Apotex: 
Abirateronesavings.com

Apoassist.com

Tablet, PO, 60mg, 240mg

60mg: 02478374

240mg: 02540185
 

Group 2*  

Eligibility:
•    Apalutamide in combination with ADT for the treatment of patients with nmCRPC who are at high risk of developing metastases. High risk defined as:
o    PSADT ≤ 10 months, during continuous ADT/post orchiectomy
•    Patients may receive only one of these agents (darolutamide, apalutamide or enzalutamide) in this setting and switching only if intolerant (without progression)

*Cancer Drugs in group 2 of the Schedule may be dispensed by a Cancer Pharmacy only if the initial prescription is written by a Cancer Centre Medical Staff member, but a subsequent prescription for the same patient may be written by a person authorized by Alberta Health Services to prescribe Cancer Drugs and who is a physician, a regulated member under the Health Professions Act authorized to prescribe drugs, or a person authorized to prescribe drugs pursuant to another enactment.

Groupe 2*
Admissibilité :
•    L’apalutamide en association avec un TAA pour le traitement des patients atteints de CPRCnm qui présentent un risque élevé de développer des métastases. Risque élevé défini comme suit :
o    TDAPS ≤ 10 mois, pendant un TAA continu/après une orchidectomie
•    Les patients ne peuvent recevoir qu’un seul de ces agents (darolutamide, apalutamide ou enzalutamide) dans ce contexte et peuvent passer à un autre agent seulement s’ils ne tolèrent pas l’agent actuel (sans progression)
*Les médicaments anticancéreux du groupe 2 de l’annexe ne peuvent être délivrés par une pharmacie spécialisée dans le cancer que si l’ordonnance initiale est rédigée par un membre du personnel médical du Centre de cancérologie. Cependant, une ordonnance subséquente pour le même patient peut être rédigée par une personne que les Services de santé de l’Alberta autorisent à prescrire des médicaments anticancéreux et qui est médecin, membre réglementé en vertu de la Loi sur les professions de la santé autorisé à prescrire des médicaments ou encore une personne autorisée à prescrire des médicaments en vertu d’une autre promulgation.
 

AHS Outpatient Cancer Drug Benefit Program [3-22]

Janssen BioAdvance Patient Assistance Program: Access Here

Tablet, PO, 60mg, 240mg

60mg: 02478374

240mg: 02540185

Group 2*  

Eligibility:

• Apalutamide in combination with ADT for the treatment of patients with mCSPC defined as:
  • No prior ADT in the metastatic setting, OR
  • Within 6 months of beginning ADT for metastatic disease, OR
  • > 1 year since prior ADT for early-stage disease with good performance status
• Patients may receive only one of these agents (apalutamide, enzalutamide, or abiraterone) in this setting and switching only if intolerance, not progression

*Cancer Drugs in group 2 of the Schedule may be dispensed by a Cancer Pharmacy only if the initial prescription is written by a Cancer Centre Medical Staff member, but a subsequent prescription for the same patient may be written by a person authorized by Alberta Health Services to prescribe Cancer Drugs and who is a physician, a regulated member under the Health Professions Act authorized to prescribe drugs, or a person authorized to prescribe drugs pursuant to another enactment.

AHS Outpatient Cancer Drug Benefit Program [3-22]

Janssen BioAdvance Patient Assistance Program: Access Here

Oral

Not specified

Group 2*

Eligibility:

• Darolutamide in combination with ADT for the treatment of patients with nmCRPC who are at high risk of developing metastases. High risk defined as:

• PSADT ≤ 10 months during continuous ADT/post orchiectomy

• Patients may receive only one of these agents (darolutamide, apalutamide or enzalutamide) in this setting and switching only if intolerant (without progression)

*Cancer Drugs in group 2 of the Schedule may be dispensed by a Cancer Pharmacy only if the initial prescription is written by a Cancer Centre Medical Staff member, but a subsequent prescription for the same patient may be written by a person authorized by Alberta Health Services to prescribe Cancer Drugs and who is a physician, a regulated member under the Health Professions Act authorized to prescribe drugs, or a person authorized to prescribe drugs pursuant to another enactment.

AHS Outpatient Cancer Drug Benefit Program [3-22]

NUBEQA® DART Patient Support Program: 

Toll free:  

1-833-955-3278 

Fax: 

1-877-208-4393 

Email: 

info@dartsupport.ca 

Oral

Not specified

Group 2* 

Eligibility: 

• Darolutamide in combination with docetaxel and androgen deprivation therapy (ADT) for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC) (defined as no prior ADT in the metastatic setting, or within 6 months of beginning ADT for metastatic disease, or more than 1 year after completing adjuvant ADT in the non-metastatic setting).  

• Patients are not eligible if they have received prior treatment with an androgen receptor-axis-targeted therapy (ARAT), chemotherapy, or immunotherapy for prostate cancer.  

• Patients should be chemotherapy-eligible and have good performance status. 

• Patients unable to tolerate docetaxel (with no progression) are eligible to continue with darolutamide + ADT. Patients unable to tolerate darolutamide (with no progression) may switch to a different ARAT + docetaxel + ADT or an ARAT + ADT combination. 

*Cancer Drugs in group 2 of the Schedule may be dispensed by a Cancer Pharmacy only if the initial prescription is written by a Cancer Centre Medical Staff member, but a subsequent prescription for the same patient may be written by a person authorized by Alberta Health Services to prescribe Cancer Drugs and who is a physician, a regulated member under the Health Professions Act authorized to prescribe drugs, or a person authorized to prescribe drugs pursuant to another enactment. 

AHS Outpatient Cancer Drug Benefit Program 

NUBEQA® DART Patient Support Program: 

Toll free:  

1-833-955-3278 

Fax: 

1-877-208-4393 

Email: 

info@dartsupport.ca 

Inj. Sol. 
120 mg /1.7mL
 

02545764

Pending

Haven: Drug Access Canada - Haven by Sentrex Access Here

60 mg / Syr Injection

02343541

Special authorization

 Eligibility:

• Treatment of osteoporosis in patients who have:

• A high 10-year risk (> 20%) of experiencing a major osteoporotic fracture OR
  a moderate 10-year fracture risk (10-20%) and have experienced a prior fragility fracture

• AND at least one of the following:

• Oral bisphosphonates are contraindicated due to drug-induced hypersensitivity (ie, immunologically mediated), OR
• Oral bisphosphonates are contraindicated due to an abnormality of the esophagus which delays esophageal emptying, OR
• Bisphosphonates are contraindicated due to severe renal impairment (i.e. creatinine clearance < 35 mL/min), OR
• Demonstrated persistent severe gastrointestinal intolerance to a course of therapy with either alendronate or risedronate, OR
• Had an unsatisfactory response (defined as a fragility fracture despite adhering to oral alendronate or risedronate treatment fully for 1 year and evidence of a decline in BMD below pre-treatment baseline level).

Alberta Health Drug Benefit List [3-22]

ProVital Program: Access Here

120 mg / Vial Injection

02368153

Not a benefit

Alberta Health Drug Benefit List [3-22]

The VICTORY Program: Access Here

Inj. Sol. 
120 mg /1.7mL
 

02545764

Pending

Haven:

Drug Access Canada - Haven by Sentrex
 

Oral

Not specified

Group 2*  

Eligibility:

• Enzalutamide in combination with ADT for the treatment of patients with mCSPC defined as:
  • No prior ADT in the metastatic setting, OR
  • Within 6 months of beginning ADT, OR
  • > 1 year since prior ADT for early-stage disease with good performance status
• Patients may receive only one of these agents (apalutamide, enzalutamide, or abiraterone) in this setting and switching only if intolerant (without progression)
• May follow prior docetaxel for mCSPC provided treatment has been within the last 3 months and there has been no disease progression (time limited need)

*Cancer Drugs in group 2 of the Schedule may be dispensed by a Cancer Pharmacy only if the initial prescription is written by a Cancer Centre Medical Staff member, but a subsequent prescription for the same patient may be written by a person authorized by Alberta Health Services to prescribe Cancer Drugs and who is a physician, a regulated member under the Health Professions Act authorized to prescribe drugs, or a person authorized to prescribe drugs pursuant to another enactment.

AHS Outpatient Cancer Drug Benefit Program [3-22]

Xtandi Patient Assistance Program (XPAP): 

Patient Enrolment and Consent Form (English) 

Formulaire D’inscription et de Consentement du Patient (French) 

Oral

02407329 

Enzalutamide in combination with androgen deprivation therapy (ADT) for the treatment of patients with non-metastatic castration resistant prostate cancer (nmCRPC) who are at high risk of developing metastases. High risk is defined as prostate specific antigen doubling time (PSADT) of < 10 months during continuous ADT/post orchiectomy.  

Patients may receive only one of these agents (Darolutamide, apalutamide or enzalutamide) in this setting and may switch to another agent only if intolerant (without progression). 

AHS Outpatient Cancer Drug Benefit Program List 2024-02-23 (albertahealthservices.ca) 

Xtandi Patient Assistance Program (XPAP): 

Patient Enrolment and Consent Form (English) 

Formulaire D’inscription et de Consentement du Patient (French) 

Oral

Not specified

Group 2*

Eligibility:

• Enzalutamide for the treatment of mCRPC
• May not be used following apalutamide, enzalutamide, or darolutamide use in nmCRPC setting unless discontinuation due to intolerance (without progression)
• May not be used following apalutamide or enzalutamide use in mCSPC setting unless discontinuation due to intolerance (without progression)
• May be used after progression on docetaxel if not received before

*Cancer Drugs in group 2 of the Schedule may be dispensed by a Cancer Pharmacy only if the initial prescription is written by a Cancer Centre Medical Staff member, but a subsequent prescription for the same patient may be written by a person authorized by Alberta Health Services to prescribe Cancer Drugs and who is a physician, a regulated member under the Health Professions Act authorized to prescribe drugs, or a person authorized to prescribe drugs pursuant to another enactment.

AHS Outpatient Cancer Drug Benefit Program [3-22]

Xtandi Patient Assistance Program (XPAP): 

Patient Enrolment and Consent Form (English) 

Formulaire D’inscription et de Consentement du Patient (French) 

7.5mg-30mg mg / Syr Injection

3.75mg = 00884502, 7.5mg = 00836273, 11.25mg = 02239834, 22.5mg = 02230248, 30mg = 02239833

Public benefit

Dual-action tablet, PO/ Comprimé à double action, PO :100mg niraparib/500mg abiraterone acetate

02538563

Pending provincial funding decision

N/A

Janssen BioAdvance Patient Assistance Program: Acess Here

100 mg tab | 150 mg tab

100mg: 02475200 | 150mg: 02475219

Olaparib monotherapy for the treatment of metastatic castration resistant prostate cancer (mCRPC) and deleterious or suspected deleterious germline and / or somatic mutations in the homologous recombination repair (HRR) genes BRCA 1/2 or ATM who have progressed following prior treatment with an androgen receptor – axis targeted therapy (ARAT). Olaparib may be offered to patients who are unable to tolerate an ARAT. Patients who have received prior taxane based chemotherapy are eligible. 

AHS Outpatient Cancer Drug Benefit Program [3-22]

AstraZeneca Patient Support Program: Access Here
AstraZeneca Patient Assistance Program: Access Here

120mg tablet

02542137 

Pending (Positive CDA decision: relugolix | CDA-AMC)

Copay cards available from manufacturer